Chemotherapy of Pancreatic Carcinoma

Overview

Journal World J Surg

Publisher Wiley

Specialty General Surgery

Date 1984 Dec 1

PMID 6440373

Citations 1

Authors

J H Harvey

P S Schein

Affiliations

Soon will be listed here.

Citing Articles

Pancreatic cancer: the greatest oncological challenge.

Williamson R Br Med J (Clin Res Ed). 1988; 296(6620):445-6.

PMID: 3126853 PMC: 2545034. DOI: 10.1136/bmj.296.6620.445.

References

Wiggans R, Woolley P, Macdonald J, Smythe T, Ueno W, Schein P . Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer. 1978; 41(2):387-91. DOI: 10.1002/1097-0142(197802)41:2<387::aid-cncr2820410201>3.0.co;2-x. View

DuPriest Jr R, Huntington M, Massey W, Weiss A, Wilson W, FLETCHER W . Streptozotocin therapy in 22 cancer patients. Cancer. 1975; 35(2):358-67. DOI: 10.1002/1097-0142(197502)35:2<358::aid-cncr2820350210>3.0.co;2-g. View

Bukowski R, Abderhalden R, HEWLETT J, Weick J, GROPPE Jr C . Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials. 1980; 3(4):321-4. View

Lokich J, SKARIN A . Combination therapy with 5-fluorouracil (5-FU; NSC-19893) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for disseminated gastrointestinal carcinoma. Cancer Chemother Rep. 1972; 56(5):653-7. View

MOERTEL C, CHILDS Jr D, Reitemeier R, COLBY Jr M, HOLBROOK M . Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969; 2(7626):865-7. DOI: 10.1016/s0140-6736(69)92326-5. View

Stolinsky D, PUGH R, Bateman J . 5-Fluorouracil (NSC-19893) therapy for pancreatic carcinoma: comparison of oral and intravenous routes. Cancer Chemother Rep. 1975; 59(5):1031-3. View

Douglass Jr H, Lavin P, MOERTEL C . Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer. Cancer Treat Rep. 1976; 60(6):769-80. View

Carter S, Comis R . The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev. 1975; 2(3):193-214. DOI: 10.1016/s0305-7372(75)80003-x. View

Schein P, Lavin P, MOERTEL C, Frytak S, Hahn R, Oconnell M . Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report. Cancer. 1978; 42(1):19-22. DOI: 10.1002/1097-0142(197807)42:1<19::aid-cncr2820420103>3.0.co;2-4. View

10.

Smith F, Hoth D, Levin B, KARLIN D, Macdonald J, WOOLLEY 3rd P . 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer. 1980; 46(9):2014-8. DOI: 10.1002/1097-0142(19801101)46:9<2014::aid-cncr2820460920>3.0.co;2-d. View

11.

Bitran J, Desser R, Kozloff M, Billings A, Shapiro C . Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep. 1979; 63(11-12):2049-51. View

12.

Kovach J, MOERTEL C, SCHUTT A, Hahn R, Reitemeier R . Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer. 1974; 33(2):563-7. DOI: 10.1002/1097-0142(197402)33:2<563::aid-cncr2820330235>3.0.co;2-k. View